{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T21:35:26Z","timestamp":1788471326712,"version":"build-2803163510"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T00:00:00Z","timestamp":1714089600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"F2G"},{"name":"Astellas Pharma, USA"},{"name":"Immy"},{"DOI":"10.13039\/100016956","name":"Melinta Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016956","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Integrita Healthcare Education Foundation"},{"name":"Centers for Disease Control and Prevention Cooperative Agreement"},{"DOI":"10.13039\/100008333","name":"University of Alabama at Birmingham","doi-asserted-by":"publisher","award":["#CDC-RFA-CK20-2003"],"award-info":[{"award-number":["#CDC-RFA-CK20-2003"]}],"id":[{"id":"10.13039\/100008333","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,6,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Recently, increasing focus on patient input into research and healthcare improvements has fostered expanded patient-centered advocacy efforts. This first pan-fungal disease summit, part of the MYCology Advocacy, Research, &amp; Education effort, brought together patients, caregivers, and mycology experts to better document patient experiences with invasive fungal disease (IFD) and establish priorities for mycology education, advocacy, and research.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Patients who had suffered from IFD, their caregivers, clinicians, industry representatives, government officials, and patient advocacy professionals were invited. Patients and caregivers shared their stories and struggles with IFD. Breakout sessions separated mycology experts from patients and caregivers for further discussions to identify commonalities and perceived gaps and to formulate recommendations. The 2 groups then reconvened to develop consensus recommendations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>IFD patients and their caregivers shared experiences reflecting the typically lengthy prediagnosis, acute treatment, long-term treatment, and posttreatment recovery stages of IFD. They reported substantial physical, psychological, and financial burdens associated with the IFD experience, particularly related to delayed diagnoses. They reaffirmed a need for coordinated patient-centered education, peer support, and advocacy to document the burden of serious fungal infections. Mycology experts discussed strategies to address gaps in the mycology field, such as insufficient training, inadequate workforce support, and a need to partner more with patient groups.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A summit involving patients with IFD, family caregivers, and mycology experts identified a substantial nonclinical burden of disease associated with IFD. Patients and mycology experts prioritized several goals for education, advocacy, and research to raise awareness of IFD and improve outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ofid\/ofae226","type":"journal-article","created":{"date-parts":[[2024,4,26]],"date-time":"2024-04-26T04:13:11Z","timestamp":1714104791000},"source":"Crossref","is-referenced-by-count":4,"title":["Shared Vision for Improving Outcomes for Serious Fungal Diseases: Report of a Patient, Caregiver, and Clinician Summit"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-0787-6578","authenticated-orcid":false,"given":"Rob","family":"Purdie","sequence":"first","affiliation":[{"name":"Integrita Healthcare Education Foundation\/MyCare , Colorado Springs, Colorado , USA"},{"name":"Valley Fever Institute, Kern Medical , Bakersfield, California , USA"},{"name":"Taskforce of AMR Survivors, World Health Organization , Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A","family":"Tushla","sequence":"additional","affiliation":[{"name":"Integrita Healthcare Education Foundation\/MyCare , Colorado Springs, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Ferretti","sequence":"additional","affiliation":[{"name":"Integrita Healthcare Education Foundation\/MyCare , Colorado Springs, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo (Kiko)","family":"Castro","sequence":"additional","affiliation":[{"name":"Integrita Healthcare Education Foundation\/MyCare , Colorado Springs, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky","family":"Watson","sequence":"additional","affiliation":[{"name":"Integrita Healthcare Education Foundation\/MyCare , Colorado Springs, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Davis","sequence":"additional","affiliation":[{"name":"Integrita Healthcare Education Foundation\/MyCare , Colorado Springs, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brianna","family":"Raborg","sequence":"additional","affiliation":[{"name":"Integrita Healthcare Education Foundation\/MyCare , Colorado Springs, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4123-0518","authenticated-orcid":false,"given":"Patrick B","family":"Mazi","sequence":"additional","affiliation":[{"name":"Integrita Healthcare Education Foundation\/MyCare , Colorado Springs, Colorado , USA"},{"name":"Division of Infectious Diseases, Washington University , St. Louis, Missouri , USA"},{"name":"Division of Pulmonary and Critical Care Medicine, Washington University , St. Louis, Missouri , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Stroman","sequence":"additional","affiliation":[{"name":"Infectious Diseases Translational Research Unit, Augusta University , Augusta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolynn","family":"Thomas Jones","sequence":"additional","affiliation":[{"name":"College of Nursing, The Ohio State University , Columbus, Ohio , USA"},{"name":"Mycoses Study Group Education and Research Consortium , Birmingham, Alabama , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J","family":"Walsh","sequence":"additional","affiliation":[{"name":"Center for Innovative Therapeutics and Diagnostics , Richmond, Virginia"},{"name":"Departments of Medicine and Microbiology & Immunology, University of Maryland School of Medicine , Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2251-8033","authenticated-orcid":false,"given":"Tom M","family":"Chiller","sequence":"additional","affiliation":[{"name":"Mycotic Diseases Branch, Centers for Disease Control and Prevention , Atlanta, Georgia , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7219-8242","authenticated-orcid":false,"given":"Peter G","family":"Pappas","sequence":"additional","affiliation":[{"name":"Mycoses Study Group Education and Research Consortium , Birmingham, Alabama , USA"},{"name":"University of Alabama at Birmingham, Division of Infectious Diseases , Birmingham, Alabama , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Meyer","sequence":"additional","affiliation":[{"name":"Integrita Healthcare Education Foundation\/MyCare , Colorado Springs, Colorado , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7612-4710","authenticated-orcid":false,"given":"Andrej","family":"Spec","sequence":"additional","affiliation":[{"name":"Integrita Healthcare Education Foundation\/MyCare , Colorado Springs, Colorado , USA"},{"name":"Division of Infectious Diseases, Washington University , St. Louis, Missouri , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,4,26]]},"reference":[{"key":"2024062706260826400_ofae226-B1","first-page":"S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"12","author":"Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2024062706260826400_ofae226-B2","doi-asserted-by":"crossref","first-page":"ofac097","DOI":"10.1093\/ofid\/ofac097","article-title":"Economic burden of fungal diseases in the United States","volume":"9","author":"Benedict","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2024062706260826400_ofae226-B3","author":"World Health Organization","year":"2022"},{"key":"2024062706260826400_ofae226-B4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1136\/ejhpharm-2020-002604","article-title":"Antifungal drug resistance: an update","volume":"29","author":"Denning","year":"2022","journal-title":"Eur J Hosp Pharm"},{"key":"2024062706260826400_ofae226-B5","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41579-022-00720-1","article-title":"Tackling the emerging threat of antifungal resistance to human health","volume":"20","author":"Fisher","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"2024062706260826400_ofae226-B6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2147\/IDR.S124918","article-title":"Antifungal resistance: current trends and future strategies to combat","volume":"10","author":"Wiederhold","year":"2017","journal-title":"Infect Drug Resist"},{"key":"2024062706260826400_ofae226-B7","doi-asserted-by":"crossref","first-page":"94","DOI":"10.5582\/irdr.2014.01015","article-title":"The Ice Bucket Challenge: the public sector should get ready to promptly promote the sustained development of a system of medical care for and research into rare diseases","volume":"3","author":"Song","year":"2014","journal-title":"Intractable Rare Dis Res"},{"key":"2024062706260826400_ofae226-B8","volume-title":"And the band played on","author":"Shilts","year":"1987"},{"key":"2024062706260826400_ofae226-B9","author":"Wolfe","year":"2023"},{"key":"2024062706260826400_ofae226-B10","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1513\/pats.200703-040BR","article-title":"Advancing outcome measures for the new era of drug development in cystic fibrosis","volume":"4","author":"Mayer-Hamblett","year":"2007","journal-title":"Proc Am Thorac Soc"},{"key":"2024062706260826400_ofae226-B11","year":"2023"},{"key":"2024062706260826400_ofae226-B12","author":"MSGERC and Terranova Medica, LLC","year":"2023"},{"key":"2024062706260826400_ofae226-B13","author":"American Valley Fever Association","year":"2023"},{"key":"2024062706260826400_ofae226-B14","author":"McCarthy","year":"2022"},{"key":"2024062706260826400_ofae226-B15","author":"The Henry Schueler 41 & 9 Foundation"},{"key":"2024062706260826400_ofae226-B16","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1093\/cid\/ciab904","article-title":"FDA public workshop summary-coccidioidomycosis (Valley Fever): considerations for development of antifungal drugs","volume":"74","author":"O'Shaughnessy","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"Suppl 28","key":"2024062706260826400_ofae226-B17","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1200\/JCO.2022.40.28_suppl.113","article-title":"Reunidos: farmworker skin cancer health navigation program","volume":"40","author":"Savage","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2024062706260826400_ofae226-B18","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/cid\/cir862","article-title":"Meeting the challenges of an emerging pathogen: the Henry Schueler 41&9 Foundation International Forum on Mucormycosis","volume":"54","author":"Walsh","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"Suppl 8","key":"2024062706260826400_ofae226-B19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1200\/JCO.2019.37.8_suppl.75","article-title":"Managing immune-related adverse events (irAEs): a new educational resource for health care professionals (HCPs) and patients","volume":"37","author":"Wood","year":"2019","journal-title":"J Clin Oncol"},{"key":"2024062706260826400_ofae226-B20","first-page":"157","article-title":"The utility of patient engagement in drug research and development","volume":"35","author":"Patel","year":"2021","journal-title":"Pharmaceut Med"},{"key":"2024062706260826400_ofae226-B21","author":"Food and Drug Administration","year":"2023"},{"issue":"Suppl 2","key":"2024062706260826400_ofae226-B22","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1093\/mmy\/myy081","article-title":"Why are so many cases of invasive aspergillosis missed?","volume":"57","author":"Danion","year":"2019","journal-title":"Med Mycol"},{"key":"2024062706260826400_ofae226-B23","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3390\/jof8050438","article-title":"Frequency and duration of, and risk factors for, diagnostic delays associated with histoplasmosis","volume":"8","author":"Miller","year":"2022","journal-title":"J Fungi (Basel)"},{"key":"2024062706260826400_ofae226-B24","doi-asserted-by":"crossref","first-page":"100563","DOI":"10.1016\/j.eclinm.2020.100563","article-title":"Potential missed opportunities for diagnosis of cryptococcosis and the association with mortality: a cohort study","volume":"27","author":"Salazar","year":"2020","journal-title":"EClinicalMedicine"},{"key":"2024062706260826400_ofae226-B25","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12929-023-00926-2","article-title":"Diagnosis of invasive fungal infections: challenges and recent developments","volume":"30","author":"Fang","year":"2023","journal-title":"J Biomed Sci"},{"key":"2024062706260826400_ofae226-B26","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.3201\/eid2508.190019","article-title":"Delays in coccidioidomycosis diagnosis and relationship to healthcare utilization, Phoenix, Arizona, USA","volume":"25","author":"Ginn","year":"2019","journal-title":"Emerg Infect Dis"},{"key":"2024062706260826400_ofae226-B27","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1086\/648724","article-title":"Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy","volume":"50","author":"Hage","year":"2010","journal-title":"Clin Infect Dis"},{"key":"2024062706260826400_ofae226-B28","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2146\/ajhp080325","article-title":"Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients","volume":"66","author":"Menzin","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"2024062706260826400_ofae226-B29","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1186\/s12885-018-4868-6","article-title":"Patients' quality of life during active cancer treatment: a qualitative study","volume":"18","author":"Sibeoni","year":"2018","journal-title":"BMC Cancer"},{"key":"2024062706260826400_ofae226-B30","author":"Harrington","year":"2021"},{"key":"2024062706260826400_ofae226-B31","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.mpsur.2020.11.005","article-title":"Long-term outcomes from critical care","volume":"39","author":"Morgan","year":"2021","journal-title":"Surgery (Oxf)"},{"key":"2024062706260826400_ofae226-B32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13054-021-03535-3","article-title":"Long-term outcomes after critical illness: recent insights","volume":"25","author":"Rousseau","year":"2021","journal-title":"Crit Care"},{"key":"2024062706260826400_ofae226-B33","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.3201\/eid2810.220391","article-title":"Demographic and socioeconomic factors associated with fungal infection risk, United States, 2019","volume":"28","author":"Rayens","year":"2022","journal-title":"Emerg Infect Dis."}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofae226\/57335377\/ofae226.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/6\/ofae226\/58216149\/ofae226.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/11\/6\/ofae226\/58216149\/ofae226.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T06:54:27Z","timestamp":1719471267000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofae226\/7658482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,26]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofae226","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,6]]},"published":{"date-parts":[[2024,4,26]]},"article-number":"ofae226"}}